COMP <GO>
CBIO vs JNJ // PIOTROSKI F-SCORE QUALITY
Crescent Biopharma Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CBIO 1
— JNJ 7
▲ PIOTROSKI F-SCORE QUALITY LEADER: JNJ
LAST: $13.48 (-4.19%) • MKT CAP: $522.6M
piotroski-score
3/9
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CBIO VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CBIO | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -13.86% | 2.97% | -16.83 | JNJ | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 1.40% | 28.50% | -27.10 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | — | 6.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.36 | 5.59 | +0.77 | CBIO | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 3/9 | 8/9 | -5.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.1 | 62.1 | -11.00 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $522.6M | $662.49B | -$661.97B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CBIO REV | JNJ REV | CBIO GROSS % | JNJ GROSS % | CBIO FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $10.8M | $94.19B | — | 67.9% | -$72.5M | $19.70B |
| FY 2024 | $0 | $88.82B | — | 69.1% | -$31.1M | $19.84B |
| FY 2023 | $0 | $85.16B | — | — | -$34.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CBIO // BETA —
JNJ // BETA 1.08